Pharmacokinetic Optimization of Phage Particles for Gene-Delivery
	Andrew Baird Professor University of California at San Diego

Andrew Baird—Professor at University of California at San Diego—received PhD in biochemistry (McGill University, Montreal Canada, 1979) and did his post doctoral fellowship at the Salk Institute for Biological Studies where he remained on faculty until 1990 until becoming Professor at The Scripps Institutes for Medical Sciences. In 1995, he moved his laboratories to Prizm Pharmaceuticals (later Selective Genetics) where he led the drug discovery and drug development R&D groups. After moving a small molecule drug, a peptide therapeutic and gene based medicine from discovery and into pre-clinical and later clinical development, in 2001 he assumed a Professorship and the Directorship of the Sackler Institute of Pharmaceutical Sciences at Kings’ College, London. He is now Professor of Surgical Pharmaceutics in the University of California San Diego School of Medical Sciences.

Dr Baird is the inventor on over 40 issued US patents and the recipient of awards from the Japanese Inflammation Society (Tokyo), the Kroc Lecture (Miami), The Sister Mary Doyle Lecture (London) and MGSS (Montreal). His work has been currently funded with grants from the Department of Defense (gene medicine delivery), CDMRP and CBCRP (cancer stem cells and metastasis), and the NIH (CNS drug delivery and wound healing). He is currently the Director of one of four NIH funded Centers for Innovation in Wound Healing Research. His major research interests include targeted drug and gene delivery, phage nanobiotechnology, CNS drug delivery, biotherapeutics development and growth factors. www.ciwhr.org)

Speaking in the special symposium on Phage Nanobiotechnology.